Proscia secures million for AI technology that analyzes biopsy images in Philadelphia.
A Philadelphia-based software startup is poised to transform the realm of pathological analysis through innovative technology that leverages artificial intelligence for enhanced image evaluation. Proscia, located in Center City, has secured million in funding aimed at further developing its AI-driven software platform, Concentriq. This latest round of investment, led by Insight Partners—a prominent global software investment firm—brings the company’s total funding to 0 million.
Pathology traditionally relies on numerous individual slides that specialist pathologists must examine under a microscope to identify abnormal cells indicative of conditions like cancer. This conventional method is not only labor-intensive but also inherently subjective, as different pathologists may interpret the same slide in varying ways. Proscia aims to address these limitations with Concentriq, which employs sophisticated AI to rapidly and systematically analyze cellular patterns, enhancing both accuracy and efficiency in diagnostics.
The objective of this technological advancement is not to supplant human pathologists but to act as a supportive tool that accelerates the diagnostic process. Insights from a collaborative study between Proscia and Quest Diagnostics reveal that pathologists using the Concentriq platform are capable of evaluating nearly 2.9 patient cases per hour, a notable increase from the standard rate of 1.2 cases when utilizing traditional microscope technology. The AI component effectively guides pathologists to focus on critical areas of interest, which may otherwise be overlooked in the vast sea of benign tissue.
Each image analyzed through Concentriq ranges from 1 to 20 gigabytes, offering exceptionally high resolution that permits pathologists to zoom in on cellular and subcellular details. Such advanced imaging capabilities substantiate the tool’s potential for elevating diagnostic precision and speed.
Furthermore, Proscia’s platform is gaining traction in the pharmaceutical sector, where it assists in monitoring patient responses during clinical trials, helping identify suitable candidates for new therapeutic options. With the recent funding, Proscia plans to enhance its AI offerings and expand its workforce, anticipating an increase of up to 100 employees over the next 18 months to grow its current staff of 50.
As the field of pathology evolves with technology, Proscia stands at the forefront, eager to usher in a new era of diagnostic efficacy and patient care. Media News Source.
